Revolution Medicines R&D President Steve Kelsey to retire Jan 2027, transitions to advisor Jul 2026

Filed June 22, 2026 · Period ending June 18, 2026 · ~1 min read

Key Changes

• high

  Steve Kelsey, President of R&D, announced retirement effective Jan 4, 2027, with transition to senior advisor to CEO starting Jul 1, 2026, providing six-month handoff period.

  Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR →
• medium

  Company contemplates appointing Kelsey to board of directors upon retirement, subject to board approval, retaining his expertise in governance role.

  Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR →
• medium

  Annual meeting elected two Class III directors: Mark Goldsmith with 157.7M votes for (98.0% of votes cast, 74.2% of shares outstanding), Alexis Borisy with 127.2M votes for (79.1% of votes cast, 59.8% of shares outstanding).

  Item 5.07 — Submission of Matters to a Vote of Security Holders verify on EDGAR →